Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease is a complete reference containing updated information on the advantages and disadvantages of dual antiplatelet therapy, its duration, composition and anticipated changes. The basis for DAPT in arterial disease is discussed, allowing readers to understand platelet physiology and its relevance to ischemic events. Data on shorter than usual duration of DAPT, and on extended therapy beyond the recommendation of current guidelines is presented in great detail, summarizing a large body of evidence into concrete, relevant recommendation that is readily adaptable by practicing clinicians. A clinically relevant and updated compendium of data pertaining to this field is also presented, as well as the anticipated trends and innovations likely to occur in the next 3-5 years. Summarizes a large body of evidence into concrete, relevant recommendations that is readily adapted by practicing clinicians Explores the current status of DAPT, controversial topics, and future developments and trends in this field Edited and contributed by renowned cardiologists in the field

This book focuses on the coronary bioresorbable scaffold, a new interventional treatment for coronary artery disease, differentiated from a permanent metallic stent. The book provides an overview of the technology including non-clinical studies and clinical evidences in order to help clinicians understand the appropriate application of the technology and the optimal techniques of implantation. It covers the basics of bioresorbable scaffolds; bench test results; preclinical studies; clinical evidences; and tips and tricks of implantation.

Clinical application of antithrombotic therapy in both arterial disease (acute coronary syndromes, acute MI, peripheral arterial disease, valvular heart disease, atrial fibrillation) and venous disease, (venous thromboembolic disease and pulmonary embolism). Results of major clinical trials and their implications for clinical practice.

Written by top experts in the field Platelets play a critical role in the pathophysiology of acute coronary syndromes (ACS) and thromboembolic complications associated with atrial fibrillation. Anticoagulant and antiplatelet therapies are central to the treatment of ACS and atrial fibrillation. Over the last several decades, a better understanding of the pathogenesis of coronary heart disease and atrial fibrillation has led to refinements in antithrombotic strategies and clinical outcomes. With this in mind, some of the issues outlined in this book are new insights in genetic testing and modification of individualized antiplatelet therapy based on rapid bedside platelet analyzers. Most importantly, the current update of pros and cons of novel antiplatelet agents such as prasugrel and ticagrelor are provided in detail. Conventional antiplatelet strategies with aspirin and clopidogrel are also discussed. Special attention is devoted to experimental antiplatelet agents like PAR-1 thrombin receptor antagonists or aptamers. The ability to focus on different diseases beyond ACS, including heart failure and atrial fibrillation, distinguishes this publication. Each chapter was written by top experts in the field and scientists with the utmost authority and expertise to provide cardiologists, internists, and clinical pharmacologists with the latest updates.

Platelets in Cardiovascular Disease provides an in-depth and current coverage of relevant platelet biology and antiplatelet therapy that is in clinical use today and potentially for the future. The book provides a succinct overview of the critical role of platelets in cardiovascular medicine. Cardiovascular disease is the leading cause of mortality worldwide, and recent research has found that the platelet is central to the genesis of heart attacks and stroke as well as many of the complications of angioplasty and bypass surgery. An explosion of knowledge of the biology of platelets has established their important role in the formation of blood clots and, perhaps more intriguingly, their role as inflammatory cells. This growth in information has been paralleled by the development of several drugs that can interfere with platelet action and thereby improve patient outcomes. Indeed, several antiplatelet drugs already in development may ultimately lead to marked advances in both the treatment and prevention of cardiovascular disease. Drawing upon a panel of international experts, Platelets in Cardiovascular Disease delivers a concise yet thorough review of the major developments in antiplatelet therapy. Practicing clinicians as well as those involved in the development of new antithrombotic therapies will find the book interesting and useful. Sample Chapter(s). Chapter 1: Platelet Biology the Role of Platelets in Hemostasis, Thrombosis and Inflammation (274 KB). Contents: Platelet Biology: The Role of Platelets in Hemostasis, Thrombosis and Inflammation (R C Becker); Thromboxane Antagonists (B R Dulin & S R Steinhubl); Glycoprotein IIb/IIIa Inhibitors (S J Lehman et al.); ADP Receptor Antagonists (J Karha & C P Cannon); Monitoring Antiplatelet Therapy (P Harrison & A D Michelson); Platelet Genomics (B K Jefferson et al.); Future Strategies for the Development of Antiplatelet Drugs (R A Harrington). Readership: Physicians: cardiologists, vascular medicine specialists, hematologists; physicians in training: fellows, residents, interns; pharmacists; pharmaceutical industry: scientists, sales representatives.

The Social Security Administration (SSA) uses a screening tool called the Listing of Impairments to identify claimants who are so severely impaired that they cannot work at all and thus immediately qualify for benefits. In this report, the IOM makes several recommendations for improving SSA's capacity to determine disability benefits more quickly and efficiently using the Listings.

This book is open access under a CC BY 4.0 license. This quick-reference handbook offers a concise and practical review of key aspects of the treatment of ST-segment elevation myocardial infarction (STEMI) in the era of primary percutaneous coronary intervention (PPCI). In the context of STEMI, PPCI is the preferred mode of emergency revascularization. Access to PPCI is rapidly increasing and is now routinely practiced in both general and specialist hospitals and there has been a recent emphasis on developing STEMI networks to enhance and expedite the referral pathway. This coupled with concurrent developments to enhance the safety and efficacy of the PPCI procedure has heralded an era where STEMI interventions are increasingly considered an important subspecialty within interventional cardiology. Written by leading cardiologists who have been instrumental in the adoption of PPCI in their respective institutions, the book provides junior and senior cardiologists alike with insightful and thought-provoking tips and tricks to enhance the success of PPCI procedures, which may in turn translate into direct improvements in outcomes. The book is also relevant for healthcare providers and emergency department physicians.